Discontinued — last reported Q4 '23

Business Segments · Goodwill

Pharmaceutical — Goodwill

Cardinal Health Pharmaceutical — Goodwill remained flat by 0.0% to $2.65B in Q4 2023 compared to the prior quarter. Year-over-year, this metric declined by 0.9%, from $2.67B to $2.65B. Over 2 years (FY 2021 to FY 2023), Pharmaceutical — Goodwill shows relatively stable performance with a 0.2% CAGR.

Analysis

StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ2 2014
Last reportedQ4 2023
Rolls up toGoodwill

How to read this metric

An increase indicates recent M&A activity, while a decrease may suggest impairment charges or divestitures.

Detailed definition

This represents the excess of the purchase price over the fair value of identifiable net assets acquired in business com...

Peer comparison

Standard across large-cap healthcare distributors that utilize M&A to expand service offerings or geographic reach.

Metric ID: cah_segment_pharmaceutical_goodwill

Historical Data

11 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23
Value$2.66B$2.66B$2.66B$2.66B$2.67B$2.67B$2.67B$2.67B$2.65B$2.65B$2.65B
QoQ Change+0.0%+0.0%+0.0%+0.5%+0.0%+0.0%+0.0%-0.9%+0.0%+0.0%
YoY Change+0.5%+0.5%+0.5%+0.5%-0.9%-0.9%-0.9%
Range$2.65B$2.67B
CAGR-0.2%
Avg YoY Growth-0.1%
Median YoY Growth+0.5%
Current Streak2 quarters growth

Frequently Asked Questions

What is Cardinal Health's pharmaceutical — goodwill?
Cardinal Health (CAH) reported pharmaceutical — goodwill of $2.65B in Q4 2023.
How has Cardinal Health's pharmaceutical — goodwill changed year-over-year?
Cardinal Health's pharmaceutical — goodwill decreased by 0.9% year-over-year, from $2.67B to $2.65B.
What is the long-term trend for Cardinal Health's pharmaceutical — goodwill?
Over 2 years (2021 to 2023), Cardinal Health's pharmaceutical — goodwill has grown at a 0.2% compound annual growth rate (CAGR), from $10.63B to $10.67B.
What does pharmaceutical — goodwill mean?
The value of intangible assets like brand and market position recorded on the balance sheet from past pharmaceutical business acquisitions.